Zydelig® Available at Onco360
Onco360 has been chosen as one of the select few pharmacies in the United States with access to Zydelig (idelalisib).
The U.S. Food and Drug Administration (FDA) has approved Zydelig® (idelalisib) for the treatment of three different B-cell blood cancers:
- In combination with rituximab for patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy
- As monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies
- As monotherapy for patients with small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies
Eligible patients that are prescribed Zydelig may be able to receive support and assistance through Zydelig AccessConnect™. For more information, please visit Zydelig.com.
Refering Zydelig Through Onco360
Oncomed Dba Onco360 or
2Zydelig Prescribing Information
All rights in the product names, trade names, or logos of all third-party products, whether or not appearing with the registered trademark symbol, belong exclusively to their respective owners.